Track Turn Therapeutics's long-term debt ($6M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
The latest long-term debt for TTRX is $6M as of March 2026. Investors often review this figure alongside Turn Therapeutics's historical trend and sector peers before judging valuation or financial health.
A long-term debt figure of $6M for TTRX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.
After noting TTRX's long-term debt ($6M), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Turn Therapeutics's long-term debt against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.